Study Links Ozempic to Hair Loss in Women
There have been ongoing discussions online about a potential link between Ozempic and hair loss, akin to other alleged side effects of the medication such as changes in facial features and body shape. However, it has been challenging to definitively establish these connections.
A recent study has now associated semaglutide (the generic name for Ozempic and Wegovy) with hair loss, with researchers noting a potentially greater impact on women. It is important to note that this research is preliminary and has not yet undergone peer review, a critical aspect of scientific validation.
The findings have raised concerns about the possibility of hair loss from taking semaglutide and the strategies to address it. Here are the key findings from the study and insights from medical experts.
Experts involved in the study include Gary Goldenberg, MD, from Icahn School of Medicine at Mount Sinai Hospital; Mir Ali, MD, from MemorialCare Surgical Weight Loss Center; and Ife J. Rodney, MD, from Eternal Dermatology + Aesthetics and BLCK haircare.
The study, published in medRxiv, analyzed data from over 1,900 individuals prescribed semaglutide compared to 1,300 individuals on another weight loss drug, bupropion-naltrexone (Contrave). Semaglutide belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, which regulate gut movements and appetite.
The focus was on individuals using Wegovy, an FDA-approved obesity treatment. The researchers observed a 50% higher likelihood of hair loss diagnoses in semaglutide users, with women at double the risk compared to men. Although further research is necessary, these findings warrant attention for those currently on or considering these medications.
While the study shows an association rather than causation, the possibility of semaglutide contributing to hair loss is a valid concern, as explained by Dr. Ali and Dr. Rodney. Rapid weight loss, a common result of various methods including medications, diet changes, or surgery, can impact hair growth cycles and increase the risk of hair loss.
In summary, the study highlights a potential link between semaglutide and hair loss, particularly in women, underscoring the need for further investigation and awareness among individuals using or contemplating these medications.
Rodney explains that during the telogen phase, known as shedding or resting, hair follicles can be pushed into this phase due to a condition called telogen effluvium, leading to hair loss. Dr. Gary Goldenberg, an assistant clinical professor of dermatology, notes that he has observed this phenomenon with all GLP-1s. People on semaglutide may be at risk of developing nutritional deficiencies like iron, zinc, and protein due to reduced appetite, which can weaken hair follicles and contribute to hair shedding and thinning. Semaglutide may also affect hormone levels, such as cortisol, which can indirectly impact hair health, particularly in female patients sensitive to hormonal changes.
To prevent and address hair loss while taking semaglutide, ensuring a sufficient protein intake and following dietary recommendations from healthcare providers is essential. Monitoring iron and zinc levels, and considering vitamin supplements as advised, can be beneficial. Additionally, maintaining a balanced diet rich in fruits and vegetables can help reduce the risk of nutritional deficiencies linked to hair loss. If experiencing hair loss, using topical medications like minoxidil or consulting a dermatologist for regenerative treatments can be beneficial.
It is important to note that hair loss from semaglutide is often temporary and may improve once weight stabilizes. It is advised to seek professional guidance if struggling to manage hair loss or nutritional deficiencies.
